This is a non-promotional website produced and funded by AstraZeneca, intended for UK patients who have been prescribed Calquence ▼ (acalabrutinib).

For UK members of the public, please visit https://www.astrazeneca.co.uk/

My CLL logo
My CLL logo
  • Home
  • Understanding CLL
  • About Calquence
  • Managing my CLL
  • Resources
calquence logoastrazeneca logo
 

Resources

Find everything from appointment checklists to inspiring patient videos, to support your day-to-day life with CLL

fixed nav trigger

Supporting videos
Downloadable resources
FAQs
Supporting videos
Downloadable resources
FAQs

Supporting videos

Goal setting 

Working with your healthcare team

Downloadable resources

Appointment checklist

Download

Symptom tracker

Download

Frequently Asked Questions

Chronic lymphocytic leukaemia is a slow-growing type of blood cancer that starts in B cells, a type of white blood cell that forms in the bone marrow.1

Your medicine is an oral targeted treatment that helps fight CLL cancer cells, offering an alternative to traditional chemotherapy.2,3

The most common side effects include muscle or joint pain, headache, rash, feeling tired, weakness or lack of energy, nausea, vomiting, stomach pain, constipation, diarrhoea, decreased number of red blood cells, decreased number of neutrophils (a type of white blood cells) or decreased number of platelets (cells that help blood clot), dizziness, sinusitis, nasopharyngitis, high blood pressure, infections and new cancers, including cancers of the skin.2,3

 

You should stop taking your medicine and contact a doctor or go to your nearest emergency department immediately if you experience bleeding in different sites, or infections.2,3

 

Remember everyone's treatment experience is different, so always tell your healthcare team about any new or worsening symptoms.

Always take Calquence exactly as your doctor has told you, so do check with them if you are unsure. 

 

The usual recommendation is to take one 100 mg tablet roughly every 12 hours, at the same times each day, with or without food. Swallow tablets whole with a glass of water, do not chew, crush, dissolve or divide them, as this can affect how the medicine is absorbed. 

 

It can be taken with or without food.2,3

  • If you remember within three hours of your usual time, take the missed tablet straight away, then take your next dose at the normal time.
  • If more than three hours have passed, skip the missed dose and take your next dose at the usual time.
  • Do not take two tablets together to make up for a missed dose. If you’re unsure what to do, contact your healthcare team.

If your symptoms are improving since taking Calquence, it suggests your medication may be working for you. You should continue taking your medication until you are advised otherwise by your healthcare professional.2,3

No – you should continue to take it as prescribed by your doctor.

Most people continue treatment until the medicine stops controlling the CLL or side effects outweigh the benefits. Some patients remain on Calquence for several years with regular monitoring. Alternatively, if you are prescribed acalabrutinib in combination with venetoclax, this will be given for a maximum of 14 treatment cycles (each cycle is 28 days). Your doctor will review your response at every appointment and guide any future changes.

 
  • Other supportive sources include CLL Support, Blood Cancer UK, Macmillan Cancer Support, Leukaemia Care, and the NHS website.     
  • You can access the patient information leaflet for more information on your medicine here.
  • Your clinical nurse specialist can connect you with peer-support services to help you live well with CLL.4

Abbreviations:

CLL, chronic lymphocytic leukaemia

References:

  1. Leukaemia Care. About CLL. [Internet]. Accessed November 2025. Available from https://www.leukaemiacare.org.uk/support-and-information/information-about-blood-cancer/blood-cancer-information/leukaemia/chronic-lymphocytic-leukaemia/about-cll/
  2. Package leaflet: Information for the patient Calquence® (acalabrutinib) 100 mg film-coated tablets. Accessed November 2025. Available from https://www.medicines.org.uk/emc/files/pil.14853.pdf 
  3. CALQUENCE (acalabrutinib) 100 mg film-coated tablet SmPC. Accessed November 2025. Available from: https://www.medicines.org.uk/emc/product/14853/smpc.
  4. Live well with CLL. CLL support (2019). Accessed November 2025. Available from https://images.cllsupport.org.uk/wp-content/uploads/2020/01/31110716/BOOKLET-FINAL-PROOF..pdf

GB-69344 | November 2025

▼ This medicine is subject to additional monitoring. This will allow quick identification of new safety information, and you can help by reporting any side effects you may get. See below for more information.

Reporting side effects

If you get any side effects, talk to your doctor, nurse or pharmacist. This includes any possible side effects not listed in the Patient Information Leaflet. You can also report side effects directly via the Yellow Card Scheme, website: http://yellowcard.mhra.gov.uk/. By reporting side effects you can help provide more information on the safety of medicines.

Side effects can also be reported to AstraZeneca in the following ways:

Online: https://contactazmedical.astrazeneca.com

Email: Medical.InformationUK@astrazeneca.com

This website is only intended for UK patients who have been prescribed Calquence (Acalabrutinib). It does not replace the Patient Information Leaflet, which can be found in the carton containing your medicine and should be read alongside this information. If you have any questions about your treatment, talk to your healthcare team or refer to the Patient Information Leaflet.

 

All patient images are for illustrative purposes only.

calquence logo

GB-70342 | September 2025

Privacy Notice Terms and Conditions Cookie Policy Contact Us
astrazeneca logo

Welcome to MyCLL

This website is intended only for UK patients who have been prescribed Calquence▼ (acalabrutinib). This website has been produced and funded by AstraZeneca.

 

Please select the relevant option:

I am not a UK Calquence patient >